These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 32304433

  • 1. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
    Ben Kridis W, Sghaier S, Charfeddine S, Toumi N, Daoud J, Kammoun S, Khanfir A.
    Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
    [Abstract] [Full Text] [Related]

  • 2. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S, Liu J, Guo H, Barry W, Bell R, Murray B, Lynch J, Bastick P, Chantrill L, Kiely BE, Abdi E, Rutovitz J, Asghari R, Sullivan A, Harrison M, Kohonen-Corish M, Beith J.
    JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
    [Abstract] [Full Text] [Related]

  • 3. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
    Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M.
    Circ Cardiovasc Imaging; 2012 Sep 01; 5(5):596-603. PubMed ID: 22744937
    [Abstract] [Full Text] [Related]

  • 4. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M, Patil S, Jones LW, Steingart RM, Hudis CA, Dang CT.
    Oncologist; 2016 Apr 01; 21(4):418-24. PubMed ID: 26984450
    [Abstract] [Full Text] [Related]

  • 5. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
    Dhir V, Yan AT, Nisenbaum R, Sloninko J, Connelly KA, Barfett J, Haq R, Kirpalani A, Chan KKW, Petrella TM, Brezden-Masley C.
    Int J Cardiovasc Imaging; 2019 Nov 01; 35(11):2085-2093. PubMed ID: 31197526
    [Abstract] [Full Text] [Related]

  • 6. Prolonged electromechanical delay as an early predictor of trastuzumab-induced cardiotoxicity in patients undergoing treatment for breast cancer.
    Choe JC, Choi JH, Choi JH, Ahn J, Park JS, Lee HW, Oh JH, Lee HC, Cha KS, Hong TJ.
    Clin Cardiol; 2018 Oct 01; 41(10):1308-1314. PubMed ID: 30239009
    [Abstract] [Full Text] [Related]

  • 7. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study.
    Gong IY, Ong G, Brezden-Masley C, Dhir V, Deva DP, Chan KKW, Graham JJ, Chow CM, Thavendiranathan P, Dai D, Ng MY, Barfett JJ, Connelly KA, Yan AT.
    Int J Cardiovasc Imaging; 2019 Apr 01; 35(4):653-662. PubMed ID: 30390170
    [Abstract] [Full Text] [Related]

  • 8. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH, Acuna SA, Sevick L, Yan AT, Brezden-Masley C.
    Med Oncol; 2017 Sep 01; 34(9):154. PubMed ID: 28779423
    [Abstract] [Full Text] [Related]

  • 9. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
    Fei HW, Ali MT, Tan TC, Cheng KH, Salama L, Hua L, Zeng X, Halpern EF, Taghian A, MacDonald SM, Scherrer-Crosbie M.
    Echocardiography; 2016 Apr 01; 33(4):519-26. PubMed ID: 26992012
    [Abstract] [Full Text] [Related]

  • 10. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.
    Yu AF, Flynn JR, Moskowitz CS, Scott JM, Oeffinger KC, Dang CT, Liu JE, Jones LW, Steingart RM.
    JAMA Cardiol; 2020 Mar 01; 5(3):309-317. PubMed ID: 31939997
    [Abstract] [Full Text] [Related]

  • 11. Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab.
    Bergamini C, Niro L, Springhetti P, Ferri L, Trento L, Minnucci I, Maffeis C, Tafciu E, Rossi A, Fiorio E, Benfari G, Ribichini F.
    Cardiovasc Toxicol; 2024 Jun 01; 24(6):550-562. PubMed ID: 38696070
    [Abstract] [Full Text] [Related]

  • 12. Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy.
    El-Sherbeny WS, Sabry NM, Sharbay RM.
    J Echocardiogr; 2019 Jun 01; 17(2):76-83. PubMed ID: 30099714
    [Abstract] [Full Text] [Related]

  • 13. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
    Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan V, Domchek SM, DeMichele A, Shah P, Clark AS, Fox K, Matro J, Bradbury AR, Knollman H, Getz KD, Armenian SH, Januzzi JL, Tang WHW, Liu P, Ky B.
    J Am Heart Assoc; 2020 Jan 21; 9(2):e014708. PubMed ID: 31959034
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
    Şendur MA, Aksoy S, Yorgun H, Ozdemir N, Yilmaz FM, Yazıcı O, Zungun C, Aytemir K, Zengin N, Altundag K.
    Curr Med Res Opin; 2015 Mar 21; 31(3):547-56. PubMed ID: 25586297
    [Abstract] [Full Text] [Related]

  • 15. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
    Calvillo-Argüelles O, Abdel-Qadir H, Suntheralingam S, Michalowska M, Amir E, Thavendiranathan P.
    Am J Cardiol; 2020 Apr 15; 125(8):1270-1275. PubMed ID: 32087998
    [Abstract] [Full Text] [Related]

  • 16. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
    Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nolè F, Veglia F, Cipolla CM.
    J Clin Oncol; 2010 Sep 01; 28(25):3910-6. PubMed ID: 20679614
    [Abstract] [Full Text] [Related]

  • 17. Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity.
    Bergamini C, Dolci G, Rossi A, Torelli F, Ghiselli L, Trevisani L, Vinco G, Truong S, La Russa F, Golia G, Molino A, Benfari G, Ribichini FL.
    Clin Cardiol; 2018 Mar 01; 41(3):349-353. PubMed ID: 29569424
    [Abstract] [Full Text] [Related]

  • 18. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients.
    Keramida K, Farmakis D, Bingcang J, Sulemane S, Sutherland S, Bingcang RA, Ramachandran K, Tzavara C, Charalampopoulos G, Filippiadis D, Kouris N, Nihoyannopoulos P.
    Eur J Heart Fail; 2019 Apr 01; 21(4):529-535. PubMed ID: 30811091
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH.
    JAMA Oncol; 2016 Aug 01; 2(8):1030-7. PubMed ID: 27348762
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab.
    Huang F, Brezden-Masley C, Chan KKW, Barfett JJ, Kirpalani A, Deva DP, Jimenez-Juan L, Barthur A, Song L, Chacko B, Ng MY, Connelly K, Wong KCK, Yan AT.
    Eur Radiol; 2022 Jun 01; 32(6):4234-4242. PubMed ID: 34993574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.